Table 2.

TAC-induced center ventricular hypertrophy in mice fed placebo or dabigatran etexilate chow.

		Baseline		Week 3		Week 6
	n	LV mass	LVPWD	LV mass	LVPWD	LV mass	LVPWD
Placebo + sham	6	60 ± 0.8	0.60 ± 0.02	67 ± 3.5	0.69 ± 0.05	62 ± 3.8	0.65 ± 0.04
Placebo + TAC	10	54 ± 5.6	0.53 ± 0.02	79 ± 2.9	0.81 ± 0.05	93 ± 5.8*	0.88 ± 0.03*
Dabigatran + sham	7	54 ± 2.8	0.49 ± 0.04	62 ± 1.8	0.62 ± 0.01	56 ± 3.2	0.62 ± 0.04
Dabigatran + TAC	8	62 ± 4.3	0.63 ± 0.01	73 ± 9.5	0.81 ± 0.09	78 ± 5.8*	0.81 ± 0.05*

TAC-induced center ventricular hypertrophy in mice fed placebo or dabigatran etexilate chow. LV mass presented in mg; LVPWd in mm. Data are expressed as mean ± SEM. Statistical analysis was performed by two-way ANOVA with Holm-Sidak method;

^*P<0.05 vs corresponding sham. No difference between placebo + TAC and dabigatran + TAC was observed.